Inhaled steroid prevention including ICS LABA Section 1: Introduction / Overview 1.1 Title Inhaled steroid prevention including ICS LABA 1.2 Definition Identifying the proportion of patients receiving 5 or fewer steroid inhalers including ICS LABA products. Figures are reported for a rolling 12 month period. 1.3 Reporting Practice level (aggregated to CCG). Level 1.4 Numerator Number of patients receiving 5 or fewer steroid inhalers including ICS LABA products within a rolling 12 month period. The steroid inhalers including ICS LABA products have been defined on the following BNF chemical substances: 1.5 Denominator number of patients receiving any prescription items for steroid inhalers including ICS LABA products (see numerator for list) within a rolling 12 month period. 1.7 Methodology Numerator divided by denominator, presented as a percentage Section 2: Rationale 2.1 Purpose Steroid-containing inhalers are used as maintenance therapy for COPD and asthma. They are most likely to be effective if taken regularly. This metric shows the number of patients who have collected 5 or fewer prescriptions for preventer medication, and who might benefit from a medication review with respect to adherence. 2.2 Evidence and Regular maintenance treatment is recommended by both NICE and BTS. Policy Base Prescribing of montelukast Section 1: Introduction / Overview 1.1 Title Prescribing of montelukast 1.2 Definition Identifying the proportion of prescribing for montelukast in relation to the number of patients on the asthma register, on the data available via QOF (AST003). 1.3 Reporting Practice level (aggregated to CCG). Level 1.4 Numerator Number of prescription prescribed for any Montelukast products. The Montelukast products has been defined based on the following BNF chemical substance: 1.5 Denominator Number of patients on the asthma register, based on figures available from QoF (AST003). Data for the denominator is only available as a figure for a complete financial year and is published annually in November. As the comparator is reported on a monthly basis, the same figure is used for each month within the financial year. The latest available data will be reported until a new QOF dataset is published at which point the figures will be retrospectively adjusted accordingly.
Inhaled steroid prevention including ICS LABA Section 1: Introduction / Overview 1.1 Title Inhaled steroid prevention including ICS LABA 1.2 Definition Identifying the proportion of patients receiving 5 or fewer steroid inhalers including ICS LABA products. Figures are reported for a rolling 12 month period. 1.3 Reporting Level Practice level (aggregated to CCG). 1.4 Numerator Number of patients receiving 5 or fewer steroid inhalers including ICS LABA products within a rolling 12 month period. The steroid inhalers including ICS LABA products have been defined on the following BNF chemical substances: 1.5 Denominator number of patients receiving any prescription items for steroid inhalers including ICS LABA products (see numerator for list) within a rolling 12 month period. 1.7 Methodology Numerator divided by denominator, presented as a percentage Section 2: Rationale 2.1 Purpose Steroid-containing inhalers are used as maintenance therapy for COPD and asthma. They are most likely to be effective if taken regularly. This metric shows the number of patients who have collected 5 or fewer prescriptions for preventer medication, and who might benefit from a medication review with respect to adherence. 2.2 Evidence and Policy Base Regular maintenance treatment is recommended by both NICE and BTS. Prescribing of montelukast Section 1: Introduction / Overview 1.1 Title Prescribing of montelukast 1.2 Definition Identifying the proportion of prescribing for montelukast in relation to the number of patients on the asthma register, on the data available via QOF (AST003). 1.3 Reporting Level Practice level (aggregated to CCG). 1.4 Numerator Number of prescription prescribed for any Montelukast products. The Montelukast products has been defined based on the following BNF chemical substance: 1.5 Denominator Number of patients on the asthma register, based on figures available from QoF (AST003). Data for the denominator is only available as a figure for a complete financial year and is published annually in November. As the comparator is reported on a monthly basis, the same figure is used for each month within the financial year. The latest available data will be reported until a new QOF dataset is published at which point the figures will be retrospectively adjusted accordingly.
Respiratory%20Dashboard%20Comparator%20Descriptions%20and%20Specifications%20v0.1%20May%202018.docx